文献速递甲状腺疾病

术前分子检测发现THADA-IGF2BP3融合阳性甲状腺结节的临床病理特征

Clinicopathologic Characteristics of Thyroid Nodules Positive for the THADA-IGF2BP3 Fusion on Preoperative Molecular Analysis.
PubMed 文献 · Thyroid · 2021-03-04

该研究回顾性分析30例术前FNA分子检测THADA-IGF2BP3融合阳性的甲状腺结节,占1280例分子检测结节的约2%。77%为需手术的甲状腺肿瘤(主要为包裹性FVPTC或NIFTP),所有癌均为低风险,可能适合腺叶切除。

要点

  • THADA-IGF2BP3融合在分子检测结节中约占2%。
  • 融合阳性结节中77%为需手术的甲状腺肿瘤。
  • 所有恶性均为低风险包裹性FVPTC,可能适合腺叶切除。

核心结论

  • THADA-IGF2BP3融合阳性甲状腺结节中77%为需手术的甲状腺肿瘤,但所有癌均为低风险包裹性FVPTC,可能适合腺叶切除。

研究设计与样本

  • 回顾性研究,纳入2017年11月至2019年8月FNA样本ThyroSeq v3 GC检测THADA-IGF2BP3融合阳性结节30例。

主要发现

  • 30例融合阳性结节约占1280例分子检测结节的2%。
  • 27例有细胞学诊断数据者中,22例(81%)为AUS,3例(11%)为滤泡性肿瘤,良性及可疑恶性各1例(4%)。
  • 所有结节未发现其他突变或基因融合。
  • 24例有临床数据者中,22例(92%)接受手术,14例(64%)腺叶切除,8例(36%)全甲状腺切除;初始腺叶切除者3例(21%)行补充手术。
  • 手术病理:7例(32%)为恶性(6例EFVPTC,1例微小浸润型FVPTC),10例(45%)为NIFTP,5例(23%)为滤泡性腺瘤。

关键数值与推荐

  • 恶性、NIFTP和滤泡性腺瘤的结节大小相似(分别为2.6、2.7和2.3 cm;p=0.77)。
  • 融合阳性恶性均为甲状腺内病变,无侵袭性组织学。
  • 6例恶性融合阳性结节和4例NIFTP患者有限随访(平均18个月)未见肿瘤复发。

临床怎么用

  • 术前分子检测发现THADA-IGF2BP3融合阳性提示结节可能为低风险甲状腺肿瘤,包括FVPTC或NIFTP。
  • 对于融合阳性结节,若手术,腺叶切除可能足以充分治疗。

局限性

  • 随访时间有限(平均18个月),仅部分患者有随访数据。
  • 回顾性研究,样本量较小(30例)。
  • 临床数据仅24例可用,细胞学诊断数据仅27例可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Thyroid adenoma-associated (THADA)-IGF2BP3 fusions have been identified as an oncogenic event in thyroid neoplasms. However, the prevalence of this gene fusion and associated phenotypical and clinical features are not well defined. The aim of this study was to characterize thyroid nodules positive for THADA-IGF2BP3 fusions on preoperative molecular analysis, review surgical outcomes, and explore potential impact of the fusion detection on patient management. Methods: Thyroid nodules positive for THADA-IGF2BP3 fusion on ThyroSeq v3 genomic classifier (GC) testing of fine needle aspiration (FNA) (n = 30) samples from November 2017 to August 2019 were identified. Demographic and clinical data were obtained by retrospective chart review; pathology slides were re-examined. Results: Thirty nodules positive for THADA-IGF2BP3 fusion on FNA were identified, representing ∼2% of 1280 nodules that underwent molecular analysis. Of the 27 nodules with available cytology diagnosis data, 22 (81%) were diagnosed as atypia of undetermined significance, 3 (11%) as follicular neoplasm, and 1 (4%) each were benign, and suspicious for malignancy. No additional mutations or gene fusions were identified in any of the nodules. Of the 24 cases with available clinical data, 22 (92%) THADA-IGF2BP3-positive nodules were managed surgically, 14 (64%) by thyroid lobectomy, and 8 (36%) by total thyroidectomy. Of the patients who had initial lobectomy, 3 (21%) had completion surgery. On surgical pathology, 7 (32%) THADA-IGF2BP3-positive nodules were malignant (six encapsulated follicular variant papillary thyroid carcinomas (EFVPTC), one minimally infiltrative FVPTC), 10 (45%) noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP), and 5 (23%) follicular adenomas (FA). THADA-IGF2BP3-positive malignancies were intrathyroidal, without aggressive histology. Nodule size was similar between malignant nodules, NIFTP, and FA (2.6, 2.7, and 2.3 cm, respectively; p = 0.77). On limited follow-up (mean, 18 months) available for six patients with malignant fusion-positive nodule and 4 patients with NIFTP, no tumor recurrences were found. Conclusions: In this series of patients, 77% of THADA-IGF2BP3 fusion-positive thyroid nodules were thyroid tumors requiring surgery, either papillary carcinoma or NIFTP. However, all cancers were low risk, predominantly encapsulated FVPTCs and thus can likely be adequately treated with lobectomy.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Morariu EM, McCoy KL, Chiosea SI, et al. Clinicopathologic Characteristics of Thyroid Nodules Positive for the THADA-IGF2BP3 Fusion on Preoperative Molecular Analysis. Thyroid. 2021. PMID: 33487086. doi:10.1089/thy.2020.0589

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。